Cavli Wireless Is Set to Unveil the Next Generation of LPWAN-based IoT with C42GM Smart Cellular IoT Module at Embedded World 2022, Germany.
17.6.2022 13:31:00 EEST | Business Wire | Press release
Cavli Wireless will participate in the Embedded World 2022 edition in Nuremberg, Germany, from June 21-23, 2022. The Embedded World event is the world's biggest trade fair for everything Embedded, from electronic systems, distributed intelligence, the Internet of Things, e-mobility, energy efficiency, and much more. The company will be exhibiting its IoT connectivity solutions in hall 5, booth no: 5-362.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220617005168/en/
Powering the next generation of LPWAN IoT with Cavli C42GM Smart Cellular IoT Module (Graphic: Business Wire)
The premier showcase at the Cavli booth will be the new launch of the C42GM LTE CAT M1/NB1/NB2 compatible Smart Cellular IoT Module, which can be deployed across the globe, making it an ideal solution for logistics, automotive, vehicle tracking systems, and more.
C42GM is a dual-mode LTE CAT M1/NB1/NB2 (upgradable to Release 14) compatible Smart Cellular Module, based on 3GPP Release 13, that comes with an integrated eSIM. C42GM has a battery life profile of ten years due to Deep Sleep Mode capability. It also comes with integrated GNSS and Sigfox radio capability that can equip OEMs to explore use cases that need the hybrid LPWAN approach. As John Mathew, Chief Technology Architect at Cavli Wireless, quoted, “the integrated eSIM coupled with pre-loaded global connectivity further cements the C42GM as the world's most powerful LPWAN-based cellular IoT module."
By virtue of the Hubble Stack Intelligence, C42GM can be managed via Hubble Lens, an advanced remote diagnosis feature of the Cavli Hubble IoT Management platform wherein a customer or a Cavli Support Engineer can remotely diagnose, monitor & debug the field device with zero physical intervention, thereby paving the way for the true scaling of IoT.
Due to Cavli’s strong operator partnerships in the EU, we have an extensive footprint across Europe for our local LTE as well LTE-M connectivity offering, which is unparalleled in the industry in terms of service quality & pricing.
Join Cavli Wireless on June 22 at 16:00 GMT and participate in the exhibitor's forum where Thomas Fesquet, Business Engagement Manager for Cavli Wireless will be unveiling C42GM for our European customers & technology partners visiting the Embedded World event. Watch this video by Cavli Wireless for more information https://www.youtube.com/watch?v=DfyRiYjpkdM
"The Embedded World 2022 event is the premier trade fair for technology companies from around the globe to present their flagship offerings," said Tarun Thomas George, Chief Operating Officer at Cavli Wireless. "We are beyond excited to be a part of this prestigious event, share the stage alongside industry heavyweights, and demonstrate to the world how Cavli Wireless is democratizing the Internet of Things."
About Cavli Wireless
Cavli Wireless designs and manufactures industrial-grade cellular IoT smart modules that improve equipment reliability and expedite development processes for various applications. Cavli's smart cellular modules are equipped with global cellular connectivity through integrated eSIM functionality that provides users affordable international data pricing, simplified device management, and centralized subscription management through the proprietary cloud-based platform Cavli Hubble.
About Embedded World
Every year, the Embedded World Exhibition & Conference in Nuremberg offers the embedded community the opportunity to learn about innovations, exchange ideas, and maintain and establish valuable contacts. Exhibitors present state-of-the-art on all facets of embedded technologies, from components, modules, and complete systems to operating systems and software, hardware and software tools, and services related to embedded systems.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220617005168/en/
Contact information
Ajit Thomas, CMO, Cavli Wireless Inc
ajit@cavliwireless.com
+1-650-535-1150
https://www.cavliwireless.com/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom